Professor Dr Abhimanyu Veerakumarasivam’s career is built on a tripartite mission that focuses on building scientific education, research and service excellence in Malaysia and the ASEAN region. His research work in cancer genetics has been published in various high-impact peer-reviewed publications. In recognition of his achievements, he has won multiple awards and has been appointed to many national and international policy and strategic committees. For example, he is currently Chair of the International Network for Government Science Advice Asia Steering Committee and Chair of the Malaysian Science Outlook RDCI Committee.
Professor Veerakumarasivam also chairs the Young Scientists Network-Academy of Sciences Malaysia (YSN-ASM) that represents the top young Malaysian scientists across all scientific disciplines who contribute towards nation-building by making an impact through scientific excellence, promoting research integrity and improving public engagement in STEM. He was crowned the Best Science Communicator at the 2016 International Famelab Finals in the UK.
Academic & Professional Qualifications
PhD (Oncology & Genetics), University of Cambridge, UK (2009)
Research ethics (responsible conduct of research)
Mokhtaruddin, N. S. M., Yusof, E. N. M., Ravoof, T. B., Tiekink, E. R., Veerakumarasivam, A., & Tahir, M. I. M. (2017). Unusual saccharin-N, O (carbonyl) coordination in mixed-ligand copper (II) complexes: Synthesis, X-ray crystallography and biological activity. Journal of Molecular Structure, 1139, 1-9.
Vellasamy, S., Tong, C. K., Azhar, N. A., Kodiappan, R., Chan, S. C., Veerakumarasivam, A., & Ramasamy, R. (2016). Human mesenchymal stromal cells modulate T-cell immune response via transcriptomic regulation. Cytotherapy, 18(10), 1270-1283.
Zamanian, M., Hamadneh, L. A. Q., Veerakumarasivam, A., Rahman, S. A., Shohaimi, S., & Rosli, R. (2016). Calreticulin mediates an invasive breast cancer phenotype through the transcriptional dysregulation of p53 and MAPK pathways. Cancer Cell International, 16(1), 56.
Gurung, P., Veerakumarasivam, A., Williamson, M., Counsell, N., Douglas, J., Tan, W. S., Feber, A., Crabb S. J., Short S. C., Freeman, A, Powles, T., Hoskin, P. J., West, C. M., & Kelly, J. D. (2015). Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle_invasive bladder cancer. International Journal of Cancer, 136(3), 709-720.
Hayami, S., Yoshimatsu, M., Veerakumarasivam, A., Unoki, M., Iwai, Y., Tsunoda, T., Field, H. I., Kelly, J. D., Neal, D. E., Yamaue, H., Ponder, B. A., Nakamura, Y., & Hamamoto, R. (2010). Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Molecular Cancer, 9(1), 59.
Aitchison, A. A., Veerakumarasivam, A., Vias, M., Kumar, R., Hamdy, F. C., Neal, D. E., & Mills, I. G. (2008). Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. The Prostate, 68(6), 661-674.
Saeb-Parsy, K., Veerakumarasivam, A., Wallard, M. J., Thorne, N., Kawano, Y., Murphy, G., Neal, D.E., Mills, I. G., & Kelly, J. D. (2008). MT1-MMP regulates urothelial cell invasion via transcriptional regulation of Dickkopf-3. British Journal of Cancer, 99(4), 663.
Veerakumarasivam, A., Goldstein, L. D., Saeb-Parsy, K., Scott, H. E., Warren, A., Thorne, N. P., Mills, I.G., Venkitaraman, A., Neal, D.E., & Kelly, J. D. (2008). AURKA overexpression accompanies dysregulation of DNA-damage response genes in invasive urothelial cell carcinoma. Cell Cycle, 7(22), 3525-3533.
Veerakumarasivam, A., Scott, H. E., Chin, S. F., Warren, A., Wallard, M. J., Grimmer, D., Ichimura, K., Caldas, C., Collins, V. P., Neal, D. E., & Kelly, J. D. (2008). High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53. Clinical Cancer Research, 14(9), 2527-2534.
Vias, M., Burtt, G., Culig, Z., Veerakumarasivam, A., Neal, D. E., & Mills, I. G. (2007). A role for neurotensin in bicalutamide resistant prostate cancer cells. The Prostate, 67(2), 190-202.